Quantcast

LumiThera Receives Notice of LSDF Grant Award - KOAM TV 7

LumiThera Receives Notice of LSDF Grant Award

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE LumiThera Inc.

SEATTLE, April 28, 2014 /PRNewswire/ -- LumiThera Inc., a medical device company focused on the development of non-invasive light emitting diode (LED) treatment for ocular disorders and disease, today announced it is a recipient of a Washington State Life Sciences Discovery Award (LSDF) grant. LumiThera was 1 of 5 recipients of the LSDF grants each worth $250,000 to provide for proof of concept studies.

As stated in the LSDF press release: "LSDF created the Proof of Concept granting program to nurture the vitality and competitiveness of Washington's life sciences innovation community and help convert its 'intellectual capital' into tangible products that enhance the economic and physical health of our communities," stated John DesRosier, LSDF executive director. "By helping grantees advance their innovations from the lab into the commercial marketplace, these new awards are anticipated to improve both quality and quantity of life for individuals living with debilitating medical conditions and tobacco addiction."

"We are very honored to be a recipient of the LSDF award program.  It further validates our efforts and the need for new and early treatments for age-related macular degeneration, particularly the dry form, wherein no FDA-approved therapies exist," stated Clark Tedford, Ph.D., President and CEO. "The grant will allow us to build the unique multi-wavelength device and provides a springboard for the new company."

The grant provides for collaboration between LumiThera and Seattle-based Product Creation Studio, a design house that is providing the additional engineering resources to create the instrument. "We saw the concept that LumiThera wanted to build and were impressed with their ideas and mission to tackle global vision diseases with a non-pharmaceutical, non-invasive approach," stated Scott Thielman, Vice President, Product Creations. "We are very excited to work with them."

The grant also provides collaboration between LumiThera and Dr. Juanita Anders, Professor of Anatomy, Physiology and Genetics at Uniformed Services University of the Health Services in Bethesda and President of the American Society of Lasers in Medicine and Surgery. "Dr. Tedford, his team and I have worked in the past studying light scatter in the brain and now we will be able to investigate light scatter profiling in the eye," says Juanita Anders. "The use of low level light therapy to target key molecular endpoints involved in the AMD disease process is creative and has shown to be successful in other clinical settings."

Visit the new Company's website coming soon at www.lumithera.com.

About LumiThera Inc.

LumiThera is a developmental-stage medical device company focused on treating people affected by dry age-related macular degeneration ("AMD"). The Company was founded by a team of physicians, scientists, and engineers, with backgrounds in the use of low-level light therapy ("LLLT"), using non-invasive light emitting diodes ("LED") and laser treatments for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmologist LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.

2014 LumiThera Inc., All rights reserved.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

KOAM - Licensed to Pittsburg, Kansas
Send tips, ideas and press releases to: tips@koamtv.com
Send newsroom questions or comments to: comments@koamtv.com
Phone: (417) 624-0233 or (620) 231-0400
Web comments or questions: webmaster@koamtv.com
Newsroom Fax: (417) 624-3158

Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and KOAM. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.